ArticleThe American journal of case reports2026
Management of Bartholin's Gland Carcinoma in a Perimenopausal Woman: A Case Report.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Bartholin's gland carcinoma represents less than 5% of all vulvar cancers and is typically identified in postmenopausal women. We present a case involving a 53-year-old woman with primary Bartholin's gland carcinoma. CASE REPORT Treatment included surgical removal of the tumor, followed by chemotherapy with paclitaxel and carboplatin and adjuvant radiotherapy. Imaging studies 6 months after treatment showed no evidence of recurrence. The patient died 5 years after cancer diagnosis due to coronavirus infection. Molecular and biochemical analyses included human papillomavirus (HPV) testing and evaluation of changes in carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9) levels before lesion excision (time 0), before curettage of the uterine cavity and cervical canal (time 1), before radical lesion excision (time 2), before chemotherapy (time 3) and radiotherapy (time 4), and at 6 months after treatment completion (time 5). Histological analysis confirmed the diagnosis of Bartholin's gland carcinoma. The implemented treatment produced expected results. No HPV genotypes were detected in the tumor sample, and the patient had no history of HPV infection. Significantly (P<0.05) higher CEA and CA 19-9 levels were observed in the preoperative period compared with remission. Tumor marker levels were significantly lower after chemotherapy and radiotherapy than at diagnosis. CONCLUSIONS Paclitaxel-carboplatin chemotherapy with radiotherapy produced expected outcomes. CEA and CA 19-9 may serve as useful markers of treatment response and cancer remission. Genomic or RNA sequencing and HPV genotyping of tumor samples are advisable, given the absence of a well-defined molecular profile for Bartholin's gland carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.